KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Treasury Shares: 2011-2025

Historic Treasury Shares for Sarepta Therapeutics (SRPT) over the last 3 years, with Sep 2025 value amounting to $650,876.

  • Sarepta Therapeutics' Treasury Shares was N/A to $650,876 in Q3 2025 from the same period last year, while for Sep 2025 it was $650,876, marking a year-over-year change of. This contributed to the annual value of $2.2 million for FY2023, which is 22.46% up from last year.
  • Sarepta Therapeutics' Treasury Shares amounted to $650,876 in Q3 2025, which was up 199.98% from -$651,000 recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Treasury Shares ranged from a high of $2.2 million in Q4 2023 and a low of -$651,000 during Q2 2025.
  • Its 2-year average for Treasury Shares is $746,793, with a median of $650,876 in 2025.
  • Data for Sarepta Therapeutics' Treasury Shares shows a peak YoY surged of 39.40% (in 2021) over the last 5 years.
  • Sarepta Therapeutics' Treasury Shares (Quarterly) stood at $1.3 million in 2021, then skyrocketed by 38.59% to $1.8 million in 2022, then climbed by 22.46% to $2.2 million in 2023, then reached $650,876 in 2025.
  • Its last three reported values are $650,876 in Q3 2025, -$651,000 for Q2 2025, and $2.2 million during Q4 2023.